{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T23:22:05Z","timestamp":1794871325671,"version":"4.9.1"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Adoptive cellular therapy (ACT) with antibody-suppressor CXCR5<jats:sup>+<\/jats:sup>CD8<jats:sup>+<\/jats:sup> T cells (CD8<jats:sup>+<\/jats:sup> T<jats:sub>Ab-supp<\/jats:sub>) inhibits alloantibody production, antibody-mediated rejection (AMR), and prolongs graft survival in multiple transplant mouse models. However, it is not known how conventional immunosuppressive agents impact the efficacy of CD8<jats:sup>+<\/jats:sup> T<jats:sub>Ab-supp<\/jats:sub> ACT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>We investigated the efficacy of CD8<jats:sup>+<\/jats:sup> T<jats:sub>Ab-supp<\/jats:sub> cell ACT when combined with calcineurin inhibitor (CNi) or mammalian target of rapamycin inhibitor (mTORi) in a murine model of kidney transplant.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>ACT-mediated decrease in germinal center B cells, posttransplant alloantibody titer, and amelioration of AMR in high alloantibody-producing CCR5 knockout kidney transplant recipients were impaired when ACT was combined with CNi and enhanced when combined with mTORi. CNi (but not mTORi) reduced ACT-mediated in vivo cytotoxicity of IgG<jats:sup>+<\/jats:sup> B cells and was associated with increased quantity of germinal center B cells. Neither CNi nor mTORi treatment impacted the expression of cytotoxic effector molecules (FasL, Lamp1, perforin, granzyme B) by CD8<jats:sup>+<\/jats:sup> T<jats:sub>Ab-supp<\/jats:sub> after ACT. Concurrent treatment with CNi (but not mTORi) reduced in vivo proliferation of CD8<jats:sup>+<\/jats:sup> T<jats:sub>Ab-supp<\/jats:sub> after ACT. The increase in quantity of splenic CD44<jats:sup>+<\/jats:sup>CXCR5<jats:sup>+<\/jats:sup>CD8<jats:sup>+<\/jats:sup> T cells that occurs after ACT was reduced by concurrent treatment with CNi but not by concurrent treatment with mTORi (dose-dependent).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>Impaired efficacy of ACT by CNi is attributed to reduced persistence and\/or expansion of CD8<jats:sup>+<\/jats:sup> T<jats:sub>Ab-supp<\/jats:sub> cells after ACT. In contrast, concurrent immunosuppression with mTORi preserves CD8<jats:sup>+<\/jats:sup> T<jats:sub>Ab-supp<\/jats:sub> cells quantity, in vivo proliferation, and in vivo cytotoxic effector function after ACT and enhances suppression of humoral alloimmunity and AMR.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000004828","type":"journal-article","created":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T04:01:42Z","timestamp":1698120102000},"page":"679-692","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["CXCR5+CD8+ T Cell\u2013mediated Suppression of Humoral Alloimmunity and AMR in Mice Is Optimized With mTOR and Impaired With Calcineurin Inhibition"],"prefix":"10.1097","volume":"108","author":[{"given":"Jing L.","family":"Han","sequence":"first","affiliation":[{"name":"Department of Surgery, Comprehensive Transplant Center, The Ohio State University, Columbus, OH."},{"name":"Biomedical Sciences Graduate Program, The Ohio State University College of Medicine, Columbus, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M.","family":"Zimmerer","sequence":"additional","affiliation":[{"name":"Department of Surgery, Comprehensive Transplant Center, The Ohio State University, Columbus, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Zeng","sequence":"additional","affiliation":[{"name":"Center for Regenerative Medicine, The Research Institute at Nationwide Children\u2019s Hospital, Columbus, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachi R.","family":"Chaudhari","sequence":"additional","affiliation":[{"name":"Department of Surgery, Comprehensive Transplant Center, The Ohio State University, Columbus, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Hart","sequence":"additional","affiliation":[{"name":"Department of Surgery, Comprehensive Transplant Center, The Ohio State University, Columbus, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali A.","family":"Satoskar","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Ohio State University, Columbus, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Abdel-Rasoul","sequence":"additional","affiliation":[{"name":"Center for Biostatistics, The Ohio State University, Columbus, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher K.","family":"Breuer","sequence":"additional","affiliation":[{"name":"Center for Regenerative Medicine, The Research Institute at Nationwide Children\u2019s Hospital, Columbus, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginny L.","family":"Bumgardner","sequence":"additional","affiliation":[{"name":"Department of Surgery, Comprehensive Transplant Center, The Ohio State University, Columbus, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,10,24]]},"reference":[{"key":"R1-20250604","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1172\/JCI90597","article-title":"Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies.","volume":"127","author":"Valenzuela","year":"2017","journal-title":"J Clin Invest"},{"key":"R2-20250604","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1111\/ajt.13347","article-title":"Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody.","volume":"15","author":"Wiebe","year":"2015","journal-title":"Am J Transplant"},{"key":"R3-20250604","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1097\/TP.0b013e3182139da1","article-title":"Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes.","volume":"91","author":"Cooper","year":"2011","journal-title":"Transplantation"},{"key":"R4-20250604","first-page":"358","article-title":"De novo donor specific antibodies and patient outcomes in renal transplantation.","volume":"351","author":"DeVos","year":"2011","journal-title":"Clin Transpl"},{"key":"R5-20250604","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1600-6143.2012.04013.x","article-title":"Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant.","volume":"12","author":"Wiebe","year":"2012","journal-title":"Am J Transplant"},{"key":"R6-20250604","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1097\/TP.0b013e3181ff87f5","article-title":"Glomerular inflammation in renal allografts biopsies after the first year: cell types and relationship with antibody-mediated rejection and graft outcome.","volume":"90","author":"Papadimitriou","year":"2010","journal-title":"Transplantation"},{"key":"R7-20250604","doi-asserted-by":"crossref","first-page":"e14170","DOI":"10.1111\/ctr.14170","article-title":"Screening strategy for de novo donor-specific HLA antibodies beyond the first year after kidney transplantation: personalized or \u201cone size fits all\u201d?","volume":"35","author":"Cun","year":"2021","journal-title":"Clin Transplant"},{"key":"R8-20250604","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/TP.0000000000003095","article-title":"Recommended treatment for antibody-mediated rejection after kidney transplantation: the 2019 Expert Consensus From the Transplantation Society Working Group.","volume":"104","author":"Schinstock","year":"2020","journal-title":"Transplantation"},{"key":"R9-20250604","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/TP.0000000000002049","article-title":"The treatment of antibody-mediated rejection in kidney transplantation: an updated systematic review and meta-analysis.","volume":"102","author":"Wan","year":"2018","journal-title":"Transplantation"},{"issue":"Suppl 4","key":"R10-20250604","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/ajt.15913","article-title":"The role of novel therapeutic approaches for prevention of allosensitization and antibody-mediated rejection.","volume":"20","author":"Jordan","year":"2020","journal-title":"Am J Transplant"},{"key":"R11-20250604","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1111\/ajt.14415","article-title":"Polyclonal regulatory T cell therapy for control of inflammation in kidney transplants.","volume":"17","author":"Chandran","year":"2017","journal-title":"Am J Transplant"},{"key":"R12-20250604","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1111\/ajt.16395","article-title":"Feasibility, long-term safety, and immune monitoring of regulatory T cell therapy in living donor kidney transplant recipients.","volume":"21","author":"Harden","year":"2021","journal-title":"Am J Transplant"},{"key":"R13-20250604","doi-asserted-by":"crossref","first-page":"m3734","DOI":"10.1136\/bmj.m3734","article-title":"Regulatory T cells for minimising immune suppression in kidney transplantation: phase I\/IIa clinical trial.","volume":"371","author":"Roemhild","year":"2020","journal-title":"BMJ"},{"key":"R14-20250604","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1681\/ASN.2016111206","article-title":"Cell therapy in kidney transplantation: focus on regulatory T cells.","volume":"28","author":"Zwang","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"R15-20250604","doi-asserted-by":"crossref","first-page":"746889","DOI":"10.3389\/fimmu.2022.746889","article-title":"Utilization of Treg cells in solid organ transplantation.","volume":"13","author":"Juneja","year":"2022","journal-title":"Front Immunol"},{"key":"R16-20250604","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/MNH.0000000000000737","article-title":"Cellular therapies in kidney transplantation.","volume":"30","author":"Leclerc","year":"2021","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R17-20250604","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(20)30167-7","article-title":"Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1\/2A trials.","volume":"395","author":"Sawitzki","year":"2020","journal-title":"Lancet"},{"key":"R18-20250604","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1097\/TP.0000000000002683","article-title":"Antibody-suppressor CD8+ T cells require CXCR5.","volume":"103","author":"Zimmerer","year":"2019","journal-title":"Transplantation"},{"key":"R19-20250604","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1111\/ajt.16988","article-title":"Antibody-suppressor CXCR5+CD8+ T cellular therapy ameliorates antibody-mediated rejection following kidney transplant in CCR5 KO mice.","volume":"22","author":"Zimmerer","year":"2022","journal-title":"Am J Transplant"},{"key":"R20-20250604","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.4049\/jimmunol.2100082","article-title":"CXCR5+CD8+ T cells: a review of their antibody regulatory functions and clinical correlations.","volume":"206","author":"Elzein","year":"2021","journal-title":"J Immunol"},{"key":"R21-20250604","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1097\/TP.0000000000003151","article-title":"Inverse association between the quantity of human peripheral blood CXCR5+IFN-gamma+CD8+ T cells with de novo DSA production in the first year after kidney transplant.","volume":"104","author":"Zimmerer","year":"2020","journal-title":"Transplantation"},{"key":"R22-20250604","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1600-6143.2007.02125.x","article-title":"Acute humoral rejection of renal allografts in CCR5(-\/-) recipients.","volume":"8","author":"Bickerstaff","year":"2008","journal-title":"Am J Transplant"},{"key":"R23-20250604","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/tri.12129","article-title":"Systematic review of mouse kidney transplantation.","volume":"26","author":"Tse","year":"2013","journal-title":"Transpl Int"},{"key":"R24-20250604","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1111\/ajt.13150","article-title":"Anti-huCD20 antibody therapy for antibody-mediated rejection of renal allografts in a mouse model.","volume":"15","author":"Abe","year":"2015","journal-title":"Am J Transplant"},{"key":"R25-20250604","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.kint.2016.02.030","article-title":"Natural killer cells play a critical role in mediating inflammation and graft failure during antibody-mediated rejection of kidney allografts.","volume":"89","author":"Kohei","year":"2016","journal-title":"Kid Int"},{"key":"R26-20250604","doi-asserted-by":"crossref","first-page":"a015495","DOI":"10.1101\/cshperspect.a015495","article-title":"Lessons and limits of mouse models.","volume":"3","author":"Chong","year":"2013","journal-title":"Cold Spring Harb. Perspect Med"},{"key":"R27-20250604","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/micr.1920160212","article-title":"Improved techniques for kidney transplantation in mice.","volume":"16","author":"Zhang","year":"1995","journal-title":"Microsurgery"},{"key":"R28-20250604","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-1-4939-0345-0_3","article-title":"Pulsing dendritic cells with whole tumor cell lysates.","volume":"1139","author":"Alaniz","year":"2014","journal-title":"Methods in molecular biology (Clifton, N.J.)"},{"key":"R29-20250604","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/cmi.2016.39","article-title":"Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches.","volume":"14","author":"Diehl","year":"2017","journal-title":"Cell Mol Immunol"},{"key":"R30-20250604","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/TP.0000000000001902","article-title":"Rapamycin prolongs graft survival and induces CD4+IFN-gamma+IL-10+ regulatory type 1 cells in old recipient mice.","volume":"102","author":"Quante","year":"2018","journal-title":"Transplantation"},{"key":"R31-20250604","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0306-3623(94)00113-2","article-title":"The pharmacology of immunosuppressant drugs in skin transplant rejection in mice and other rodents.","volume":"26","author":"Gardner","year":"1995","journal-title":"Gen Pharmacol"},{"key":"R32-20250604","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1523-1755.2001.00460.x","article-title":"Rapamycin in transplantation: a review of the evidence.","volume":"59","author":"Saunders","year":"2001","journal-title":"Kidney Int"},{"key":"R33-20250604","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/ajt.12565","article-title":"Alloprimed CD8(+) T cells regulate alloantibody and eliminate alloprimed B cells through perforin- and FasL-dependent mechanisms.","volume":"14","author":"Zimmerer","year":"2014","journal-title":"Am J Transplant"},{"key":"R34-20250604","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4049\/jimmunol.179.1.80","article-title":"Disparate primary and secondary allospecific CD8+ T cell cytolytic effector function in the presence or absence of host CD4+ T cells.","volume":"179","author":"Horne","year":"2007","journal-title":"J Immunol"},{"key":"R35-20250604","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.cll.2007.05.001","article-title":"Modern flow cytometry: a practical approach.","volume":"27","author":"Tung","year":"2007","journal-title":"Clin Lab Med"},{"key":"R36-20250604","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1111\/j.1600-6143.2007.01971.x","article-title":"Synergistic deposition of C4d by complement-activating and non-activating antibodies in cardiac transplants.","volume":"7","author":"Murata","year":"2007","journal-title":"Am J Transplant"},{"key":"R37-20250604","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/ajt.13661","article-title":"The revised (2013) Banff classification for antibody-mediated rejection of renal allografts: update, difficulties, and future considerations.","volume":"16","author":"Haas","year":"2016","journal-title":"Am J Transplant"},{"key":"R38-20250604","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1600-6143.2008.02159.x","article-title":"Banff 07 classification of renal allograft pathology: updates and future directions.","volume":"8","author":"Solez","year":"2008","journal-title":"Am J Transplant"},{"key":"R39-20250604","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/ajt.14087","article-title":"Age-dependent metabolic and immunosuppressive effects of tacrolimus.","volume":"17","author":"Krenzien","year":"2017","journal-title":"Am J Transplant"},{"key":"R40-20250604","doi-asserted-by":"crossref","first-page":"903068","DOI":"10.3389\/fimmu.2022.903068","article-title":"Harnessing the B cell response in kidney transplantation\u2014current state and future directions.","volume":"13","author":"Anwar","year":"2022","journal-title":"Front Immunol"},{"key":"R41-20250604","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1097\/TP.0b013e3181ff8772","article-title":"Ex vivo-expanded human regulatory T cells prevent the rejection of skin allografts in a humanized mouse model.","volume":"90","author":"Issa","year":"2010","journal-title":"Transplantation"},{"key":"R42-20250604","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s13287-020-01721-8","article-title":"Preconditioning is an effective strategy for improving the efficiency of mesenchymal stem cells in kidney transplantation.","volume":"11","author":"Zhao","year":"2020","journal-title":"Stem Cell Res Ther"},{"key":"R43-20250604","doi-asserted-by":"crossref","first-page":"662441","DOI":"10.3389\/fimmu.2021.662441","article-title":"Efficacy and safety of bone marrow-derived mesenchymal stem cells for chronic antibody-mediated rejection after kidney transplantation\u2014a single-arm, two-dosing-regimen, phase I\/II study.","volume":"12","author":"Wei","year":"2021","journal-title":"Front Immunol"},{"key":"R44-20250604","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.ekir.2022.03.030","article-title":"Study design: human leukocyte antigen class I molecule A(*)02-chimeric antigen receptor regulatory T cells in renal transplantation.","volume":"7","author":"Schreeb","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"1 Supplement","key":"R45-20250604","doi-asserted-by":"crossref","first-page":"53.06","DOI":"10.4049\/jimmunol.208.Supp.53.06","article-title":"Alloprimed antibody-suppressor CD8+ T cells preferentially kill alloprimed germinal center B cells.","volume":"208","author":"Zimmerer","year":"2022","journal-title":"J Immunol"},{"key":"R46-20250604","doi-asserted-by":"crossref","first-page":"5238","DOI":"10.4049\/jimmunol.179.8.5238","article-title":"Antibody-mediated rejection of cardiac allografts in CCR5-deficient recipients.","volume":"179","author":"Nozaki","year":"2007","journal-title":"J Immunol"},{"key":"R47-20250604","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.anclin.2017.04.001","article-title":"Overview of immunosuppressive therapy in solid organ transplantation.","volume":"35","author":"Holt","year":"2017","journal-title":"Anesthesiol Clin"},{"issue":"Suppl 2","key":"R48-20250604","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/ajt.16982","article-title":"OPTN\/SRTR 2020 annual data report: kidney.","volume":"22","author":"Lentine","year":"2022","journal-title":"Am J Transplant"},{"key":"R49-20250604","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1097\/TP.0000000000001291","article-title":"mTOR inhibition suppresses posttransplant alloantibody production through direct inhibition of alloprimed B cells and sparing of CD8+ antibody-suppressing T cells.","volume":"100","author":"Avila","year":"2016","journal-title":"Transplantation"},{"key":"R50-20250604","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.healun.2013.11.004","article-title":"T-regulatory cell treatment prevents chronic rejection of heart allografts in a murine mixed chimerism model.","volume":"33","author":"Pilat","year":"2014","journal-title":"J Heart Lung Transplant"},{"key":"R51-20250604","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1111\/ajt.17063","article-title":"Anti-HLA-A2-CAR Tregs prolong vascularized mouse heterotopic heart allograft survival.","volume":"22","author":"Wagner","year":"2022","journal-title":"Am J Transplant"},{"key":"R52-20250604","doi-asserted-by":"crossref","first-page":"103645","DOI":"10.1016\/j.isci.2021.103645","article-title":"Translational and post-translational control of human naive versus primed pluripotency.","volume":"25","author":"Chen","year":"2022","journal-title":"iScience"},{"key":"R53-20250604","doi-asserted-by":"crossref","first-page":"657894","DOI":"10.3389\/fimmu.2021.657894","article-title":"Disruption of Tfh:B cell interactions prevents antibody-mediated rejection in a kidney transplant model in rats: impact of calcineurin inhibitor dose.","volume":"12","author":"Steines","year":"2021","journal-title":"Front Immunol"},{"key":"R54-20250604","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.3389\/fimmu.2019.02978","article-title":"Effects of antirejection drugs on innate immune cells after kidney transplantation.","volume":"10","author":"Zaza","year":"2019","journal-title":"Front Immunol"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004828","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T18:04:27Z","timestamp":1749060267000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,24]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000004828","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,24]]}}}